TJHA
FPRX

Thomas J. Herzfeld Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-50
Closed -$2K – 357
2015
Q4 		$2K Hold
50
– – ﹤0.01% 320
2015
Q3 		$1K Buy
+50
New +$1.07K ﹤0.01% 324

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Thomas J. Herzfeld Advisors's FPRX Position: Q1 2016 in Review

Thomas J. Herzfeld Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2016, closing a stake of 50 shares — an estimated $2K sold.

Thomas J. Herzfeld Advisors first reported a position in FPRX in Q3 2015 and held it in 2 quarters. The position peaked at $2K in Q4 2015. 140 funds tracked by Wall St. Rank hold FPRX as of Q1 2016.

  • Thomas J. Herzfeld Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Thomas J. Herzfeld Advisors sold 50 Five Prime Therapeutics, Inc. shares in Q1 2016, an estimated $2K.
  • Thomas J. Herzfeld Advisors first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
  • Thomas J. Herzfeld Advisors's Five Prime Therapeutics, Inc. position peaked at $2K in Q4 2015.
  • 140 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2016.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q1 2016, filed 13 May 2016.